Proteins or Peptides as Effective Weapons in Antimicrobial and Cancer Therapy

Dear Colleagues,

Proteins and peptides have emerged as powerful therapeutic agents in the fight against infectious diseases and cancer. Antimicrobial peptides (AMPs), derived from various proteins, exhibit broad-spectrum activity against bacteria, viruses, fungi, and parasites. These peptides function by disrupting microbial membranes, inhibiting key enzymes, and modulating immune responses. In addition to their antimicrobial properties, certain peptides are gaining attention for their potential in cancer therapy. They can inhibit tumour growth, induce apoptosis, and modulate the tumour microenvironment. Proteins such as lactoferrin, defensins, and cathelicidins, along with synthetic and engineered peptides, are being explored for their dual role in combating infections and cancer. Notably, lactoferrin has demonstrated both antimicrobial effects and anticancer potential, making it a promising candidate for future therapeutic development.

This Special Issue invites research exploring the mechanisms behind proteins’ or peptides’ antibacterial, antiviral, antifungal, and antiparasitic actions, as well as their ability to synergize with existing antimicrobial treatments. Additionally, this Special Issue highlights the emerging role of proteins or peptides in cancer therapy, where their anticancer properties—such as tumour growth inhibition, immune modulation, and apoptosis induction—are being actively explored. This Special Issue aims to provide a comprehensive understanding of pharmacological applications by bridging the fields of antimicrobial therapy and cancer treatment. It offers new insights into its dual therapeutic roles and prospects in clinical settings. Original papers and review articles on these and related topics are welcome.

Prof. Dr. Nidia M. León-Sicairos
Dr. Gerardo Ramírez-Rico
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Future Pharmacology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.